Patient adherence and preference considerations in managing cardiovascular risk: Focus on single pill and amlodipine/atorvastatin fixed combination

Farhan Aslam, Attiya Haque, Veronica Lee, Jo Anne Foody

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States each year. Risk factors for CVD often co-exist. Studies estimate that over half of the hypertensive population also has dyslipidemia. Observational data suggest that fewer than 10% of patients attain recommended therapeutic targets for both conditions. A variety of patient, regimen and system characteristics have been associated with the risk for non-adherence. Polypharmacy and complex drug regimens are associated with poor patient adherence and thus the use of fixed-dose combination therapies, may improve adherence by reducing the pill burden. The fixed-dose combination of amlodipine/atorvastatin offers a convenient and effective approach to manage two important CVD risk factors. The combination of amlodipine/atorvastatin has a synergistic effect. The half-life of both agents facilitates once-daily dosing and both can be administered at any time of the day with or without food. Amlodipine/atorvastatin combined pill can be used to initiate both agents or patients can be switched directly from single-agent therapy with one or both agents. The convenience of single-pill amlodipine/atorvastatin has the potential to improve patient adherence and the management of cardiovascular risk in selected patients, thereby improving clinical outcomes.

Original languageEnglish (US)
Pages (from-to)61-66
Number of pages6
JournalPatient Preference and Adherence
Volume3
DOIs
StatePublished - Mar 4 2009

Fingerprint

Patient Preference
Patient Compliance
Cardiovascular Diseases
Disease
Polypharmacy
Risk Management
Proxy
Dyslipidemias
Half-Life
Therapeutics
food
drug
death
Food
atorvastatin drug combination amlodipine
management
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Patient adherence and preference considerations in managing cardiovascular risk : Focus on single pill and amlodipine/atorvastatin fixed combination. / Aslam, Farhan; Haque, Attiya; Lee, Veronica; Foody, Jo Anne.

In: Patient Preference and Adherence, Vol. 3, 04.03.2009, p. 61-66.

Research output: Contribution to journalReview article

@article{8029202cf3264356a4533e57dab102a0,
title = "Patient adherence and preference considerations in managing cardiovascular risk: Focus on single pill and amlodipine/atorvastatin fixed combination",
abstract = "Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States each year. Risk factors for CVD often co-exist. Studies estimate that over half of the hypertensive population also has dyslipidemia. Observational data suggest that fewer than 10{\%} of patients attain recommended therapeutic targets for both conditions. A variety of patient, regimen and system characteristics have been associated with the risk for non-adherence. Polypharmacy and complex drug regimens are associated with poor patient adherence and thus the use of fixed-dose combination therapies, may improve adherence by reducing the pill burden. The fixed-dose combination of amlodipine/atorvastatin offers a convenient and effective approach to manage two important CVD risk factors. The combination of amlodipine/atorvastatin has a synergistic effect. The half-life of both agents facilitates once-daily dosing and both can be administered at any time of the day with or without food. Amlodipine/atorvastatin combined pill can be used to initiate both agents or patients can be switched directly from single-agent therapy with one or both agents. The convenience of single-pill amlodipine/atorvastatin has the potential to improve patient adherence and the management of cardiovascular risk in selected patients, thereby improving clinical outcomes.",
author = "Farhan Aslam and Attiya Haque and Veronica Lee and Foody, {Jo Anne}",
year = "2009",
month = "3",
day = "4",
doi = "10.2147/PPA.S4201",
language = "English (US)",
volume = "3",
pages = "61--66",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Patient adherence and preference considerations in managing cardiovascular risk

T2 - Focus on single pill and amlodipine/atorvastatin fixed combination

AU - Aslam, Farhan

AU - Haque, Attiya

AU - Lee, Veronica

AU - Foody, Jo Anne

PY - 2009/3/4

Y1 - 2009/3/4

N2 - Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States each year. Risk factors for CVD often co-exist. Studies estimate that over half of the hypertensive population also has dyslipidemia. Observational data suggest that fewer than 10% of patients attain recommended therapeutic targets for both conditions. A variety of patient, regimen and system characteristics have been associated with the risk for non-adherence. Polypharmacy and complex drug regimens are associated with poor patient adherence and thus the use of fixed-dose combination therapies, may improve adherence by reducing the pill burden. The fixed-dose combination of amlodipine/atorvastatin offers a convenient and effective approach to manage two important CVD risk factors. The combination of amlodipine/atorvastatin has a synergistic effect. The half-life of both agents facilitates once-daily dosing and both can be administered at any time of the day with or without food. Amlodipine/atorvastatin combined pill can be used to initiate both agents or patients can be switched directly from single-agent therapy with one or both agents. The convenience of single-pill amlodipine/atorvastatin has the potential to improve patient adherence and the management of cardiovascular risk in selected patients, thereby improving clinical outcomes.

AB - Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States each year. Risk factors for CVD often co-exist. Studies estimate that over half of the hypertensive population also has dyslipidemia. Observational data suggest that fewer than 10% of patients attain recommended therapeutic targets for both conditions. A variety of patient, regimen and system characteristics have been associated with the risk for non-adherence. Polypharmacy and complex drug regimens are associated with poor patient adherence and thus the use of fixed-dose combination therapies, may improve adherence by reducing the pill burden. The fixed-dose combination of amlodipine/atorvastatin offers a convenient and effective approach to manage two important CVD risk factors. The combination of amlodipine/atorvastatin has a synergistic effect. The half-life of both agents facilitates once-daily dosing and both can be administered at any time of the day with or without food. Amlodipine/atorvastatin combined pill can be used to initiate both agents or patients can be switched directly from single-agent therapy with one or both agents. The convenience of single-pill amlodipine/atorvastatin has the potential to improve patient adherence and the management of cardiovascular risk in selected patients, thereby improving clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=75749096893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749096893&partnerID=8YFLogxK

U2 - 10.2147/PPA.S4201

DO - 10.2147/PPA.S4201

M3 - Review article

AN - SCOPUS:75749096893

VL - 3

SP - 61

EP - 66

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -